LU91452I2 - "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" - Google Patents

"Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Info

Publication number
LU91452I2
LU91452I2 LU91452C LU91452C LU91452I2 LU 91452 I2 LU91452 I2 LU 91452I2 LU 91452 C LU91452 C LU 91452C LU 91452 C LU91452 C LU 91452C LU 91452 I2 LU91452 I2 LU 91452I2
Authority
LU
Luxembourg
Prior art keywords
mycaminer
mycafungin
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91452C
Other languages
English (en)
French (fr)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91452(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU91452I2 publication Critical patent/LU91452I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91452C 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)" LU91452I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (en) 1994-10-07 1995-09-29 Cyclic hexapeptides having antibiotic activity

Publications (1)

Publication Number Publication Date
LU91452I2 true LU91452I2 (fr) 2008-08-04

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91452C LU91452I2 (fr) 1994-10-07 2008-06-04 "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"

Country Status (26)

Country Link
US (2) US6107458A (cg-RX-API-DMAC7.html)
EP (1) EP0788511B1 (cg-RX-API-DMAC7.html)
JP (2) JP2897427B2 (cg-RX-API-DMAC7.html)
KR (1) KR100353303B1 (cg-RX-API-DMAC7.html)
CN (1) CN1203089C (cg-RX-API-DMAC7.html)
AR (1) AR041770A1 (cg-RX-API-DMAC7.html)
AT (1) ATE229541T1 (cg-RX-API-DMAC7.html)
AU (1) AU696949B2 (cg-RX-API-DMAC7.html)
BR (2) BR9504791B1 (cg-RX-API-DMAC7.html)
CA (1) CA2202058C (cg-RX-API-DMAC7.html)
DE (2) DE122008000025I2 (cg-RX-API-DMAC7.html)
DK (1) DK0788511T3 (cg-RX-API-DMAC7.html)
ES (1) ES2187575T3 (cg-RX-API-DMAC7.html)
FI (1) FI119988B (cg-RX-API-DMAC7.html)
FR (1) FR08C0028I2 (cg-RX-API-DMAC7.html)
HU (1) HU228151B1 (cg-RX-API-DMAC7.html)
IL (1) IL115484A (cg-RX-API-DMAC7.html)
LU (1) LU91452I2 (cg-RX-API-DMAC7.html)
MX (1) MX9702531A (cg-RX-API-DMAC7.html)
NL (1) NL300352I2 (cg-RX-API-DMAC7.html)
NO (2) NO328483B1 (cg-RX-API-DMAC7.html)
OA (1) OA10475A (cg-RX-API-DMAC7.html)
PT (1) PT788511E (cg-RX-API-DMAC7.html)
RU (1) RU2165423C2 (cg-RX-API-DMAC7.html)
TR (1) TR199501229A2 (cg-RX-API-DMAC7.html)
WO (1) WO1996011210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US6291680B1 (en) * 1997-06-18 2001-09-18 Fujisawa Pharmaceutical Co., Ltd. Production process
CA2320416A1 (en) * 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2251976T3 (es) * 1999-02-11 2006-05-16 Emisphere Technologies, Inc. Compuestos y composiciones de oxadiazol para aportar agentes activos.
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CA2380176A1 (en) 1999-07-27 2001-02-01 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US7199248B2 (en) 2002-08-08 2007-04-03 Astellas Pharma Inc. Process
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2005018743A1 (en) * 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
AU2004273029A1 (en) * 2003-09-05 2005-03-24 Merck & Co., Inc. Stationary phases and a purification process using the stationary phases
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20050261365A1 (en) * 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
KR20070067165A (ko) * 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. 넌센스 변이 억제용 화합물, 및 이의 사용 방법
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
WO2007043401A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
PL2786992T3 (pl) 2007-08-13 2018-04-30 Monsanto Technology Llc Kompozycje i sposoby zwalczania nicieni
AU2008319977A1 (en) * 2007-10-29 2009-05-07 Astellas Pharma Inc. Polypeptide compound
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
CA2729212C (en) * 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
BR112013026420A2 (pt) 2011-04-20 2020-11-03 Xellia Pharmaceuticals Aps método de produção de um sal de micafungina farmaceuticamente aceitável
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EP2763971B1 (en) 2011-09-09 2016-06-08 Sandoz AG Preparation of micafungin intermediates
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
CN104861044B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的溶剂合物及其制备方法和用途
WO2016056023A2 (en) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
FI3554474T3 (fi) 2016-12-16 2024-02-21 Baxter Int Mikafungiinikoostumuksia
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
FI912873A7 (fi) * 1990-06-18 1991-12-19 Fujisawa Pharmaceutical Co Uusi polypeptidiyhdiste ja menetelmä sen valmistamiseksi
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof

Also Published As

Publication number Publication date
CA2202058C (en) 2007-11-06
FR08C0028I1 (cg-RX-API-DMAC7.html) 2008-08-15
CN1168675A (zh) 1997-12-24
HUT77736A (hu) 1998-07-28
NO971544D0 (no) 1997-04-04
KR970707150A (ko) 1997-12-01
JPH10507174A (ja) 1998-07-14
NO971544L (no) 1997-06-04
FI971397L (fi) 1997-05-27
ES2187575T3 (es) 2003-06-16
IL115484A (en) 2000-07-16
KR100353303B1 (ko) 2003-01-15
NL300352I1 (nl) 2008-08-01
NO2010016I2 (no) 2011-10-17
EP0788511A1 (en) 1997-08-13
DE122008000025I1 (de) 2008-08-21
NO2010016I1 (no) 2010-08-16
DE122008000025I2 (de) 2011-02-17
JP3518665B2 (ja) 2004-04-12
PT788511E (pt) 2003-04-30
ATE229541T1 (de) 2002-12-15
AU696949B2 (en) 1998-09-24
JP2897427B2 (ja) 1999-05-31
DE69529172D1 (de) 2003-01-23
US6107458A (en) 2000-08-22
JPH10324695A (ja) 1998-12-08
NO328483B1 (no) 2010-03-01
NL300352I2 (nl) 2008-11-03
EP0788511B1 (en) 2002-12-11
DK0788511T3 (da) 2003-03-31
BR9504791B1 (pt) 2010-10-05
CA2202058A1 (en) 1996-04-18
FI119988B (fi) 2009-05-29
BR9504791A (pt) 1996-10-22
US6265536B1 (en) 2001-07-24
CN1203089C (zh) 2005-05-25
TR199501229A2 (tr) 1996-07-21
MX9702531A (es) 1997-06-28
OA10475A (en) 2002-04-08
HK1004136A1 (en) 1998-11-20
IL115484A0 (en) 1996-01-19
RU2165423C2 (ru) 2001-04-20
DE69529172T2 (de) 2003-04-17
FR08C0028I2 (cg-RX-API-DMAC7.html) 2009-11-20
FI971397A0 (fi) 1997-04-04
HU228151B1 (en) 2012-12-28
AU3578095A (en) 1996-05-02
BRPI9504791B8 (pt) 2019-12-31
AR041770A1 (es) 2005-06-01
WO1996011210A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
LU91437I2 (fr) "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)"
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU91346I2 (fr) Lumiracoxib et ses dérivés pharmaceutiquement acceptables (prexige)
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
LU92564I2 (fr) Médocaril de ceftobiprole et les sels pharmaceutiquement acceptables qui en dérivent
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
ITGE940099A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
ITMI962503A0 (it) Procedimento per progettare una apparecchiatura impiegante superconduttivita' e apparecchiatura impiegante superconduttivita'
KR940005143U (ko) 유희용 라켓
ITGE940106A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
FI943875L (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
KR940001899U (ko) 네온 변압기의 접속구
KR960038365U (ko) 피엘씨의 입출력 증설장치
GB9226874D0 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
ZA937286B (en) Immunopotentiatory agents and physiologically acceptable salts thereof
UA665S (uk) Головний убір чоловічий відомчого призначення